Nonetheless, pre-clinical studies on sVEGFR1 gene/protein therapy have already shown success in interfering with VEGF-dependent pathological processes including tumor angiogenesis [21]–[30], ocular neovascularization [31], [32], inflammation [33]–[35] and edema [36]. Here, VEGFA is linked to neoplasm.